摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexyl]-acetamide | 127946-07-0

中文名称
——
中文别名
——
英文名称
N-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexyl]-acetamide
英文别名
——
N-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexyl]-acetamide化学式
CAS
127946-07-0
化学式
C19H29N5O3
mdl
——
分子量
375.471
InChiKey
LCVFOTNHCZQVPU-HDJSIYSDSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.87
  • 重原子数:
    27.0
  • 可旋转键数:
    6.0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    101.78
  • 氢给体数:
    2.0
  • 氢受体数:
    6.0

反应信息

  • 作为产物:
    描述:
    trans-4-acetamidocyclohexanecarboxylic acid 在 sodium hydroxide盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 为溶剂, 反应 2.67h, 生成 N-[4-(2,6-Dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-cyclohexyl]-acetamide
    参考文献:
    名称:
    8-环烷基-1,3-二丙基黄嘌呤作为腺苷受体拮抗剂的构效关系。
    摘要:
    8-取代的黄嘌呤目前代表最有效的腺苷-受体拮抗剂。制备了一系列8-取代的1,3-二丙基黄嘌呤,并确定了它们分别作为人血小板和大鼠脂肪细胞的A1和A2腺苷受体拮抗剂的效力。没有研究药物能像A1腺苷受体拮抗剂那样与8-环戊基-1,3-二丙基黄嘌呤一样有效,但是8-(2-甲基环丙基)-1,3-二丙基黄嘌呤比A1腺苷受体的效力至少强1000倍。 A1比A2的腺苷受体高。虽然8-环烷基部分上的大多数取代都导致抑制A1和A2腺苷受体,8- [反式-4-(乙酰氨基甲基)环己基] -1的效力降低,
    DOI:
    10.1021/jm00169a012
点击查看最新优质反应信息

文献信息

  • Potent and Orally Bioavailable 8-Bicyclo[2.2.2]octylxanthines as Adenosine A<sub>1</sub> Receptor Antagonists
    作者:William F. Kiesman、Jin Zhao、Patrick R. Conlon、James E. Dowling、Russell C. Petter、Frank Lutterodt、Xiaowei Jin、Glenn Smits、Mary Fure、Andrew Jayaraj、John Kim、Gail Sullivan、Joel Linden
    DOI:10.1021/jm0605381
    日期:2006.11.30
    In the search for a selective adenosine A(1) receptor antagonist with greater aqueous solubility than the compounds currently in clinical trials as diuretics, a series of 1,4- substituted 8-cyclohexyl and 8-bicyclo-[2.2.2] octylxanthines were investigated. The binding affinities of a variety of cyclohexyl and bicyclo[2.2.2]octylxanthines for the rat and human adenosine A(1), A(2A), A(2B), and A(3) receptors are presented. Bicyclo[ 2.2.2] octylxanthine 16 exhibited good pharmaceutical properties and in vivo activity in a rat diuresis model (ED50=0.3 mg/ kg po). Optimization of the bridgehead substituent led to propionic acid 29 ( BG9928), which retained high potency ( hA(1), K-i=7 nM) and selectivity for the adenosine A1 receptor (915-fold versus adenosine A2A receptor; 12-fold versus adenosine A2B receptor) with improved oral efficacy in the rat diuresis model (ED50=0.01 mg/ kg) as well as high oral bioavailability in rat, dog, and cynomolgus monkey.
  • Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors
    作者:T. Katsushima、L. Nieves、J. N. Wells
    DOI:10.1021/jm00169a012
    日期:1990.7
    least 1000-fold more potent as an antagonist of A1 than of A2 adenosine receptors. While most substitutions on the 8-cycloalkyl moiety caused decreased potency to inhibit both A1 and A2 adenosine receptors, 8-[trans-4-(acetamidomethyl)cyclohexyl]-1,3-dipropylxanthine was nearly equipotent as an antagonist of the two receptors and appeared to be the most potent antagonist of A2 adenosine receptors reported
    8-取代的黄嘌呤目前代表最有效的腺苷-受体拮抗剂。制备了一系列8-取代的1,3-二丙基黄嘌呤,并确定了它们分别作为人血小板和大鼠脂肪细胞的A1和A2腺苷受体拮抗剂的效力。没有研究药物能像A1腺苷受体拮抗剂那样与8-环戊基-1,3-二丙基黄嘌呤一样有效,但是8-(2-甲基环丙基)-1,3-二丙基黄嘌呤比A1腺苷受体的效力至少强1000倍。 A1比A2的腺苷受体高。虽然8-环烷基部分上的大多数取代都导致抑制A1和A2腺苷受体,8- [反式-4-(乙酰氨基甲基)环己基] -1的效力降低,
查看更多